OLD Point Trust & Financial Services N A trimmed its holdings in Amgen Inc. (NASDAQ:AMGN) by 5.4% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 24,393 shares of the medical research company’s stock after selling 1,400 shares during the period. Amgen accounts for approximately 2.4% of OLD Point Trust & Financial Services N A’s portfolio, making the stock its 14th largest position. OLD Point Trust & Financial Services N A’s holdings in Amgen were worth $4,202,000 as of its most recent SEC filing.
Several other large investors have also made changes to their positions in the company. 1ST Source Bank raised its holdings in shares of Amgen by 1.7% in the second quarter. 1ST Source Bank now owns 3,849 shares of the medical research company’s stock valued at $663,000 after buying an additional 63 shares during the last quarter. Lederer & Associates Investment Counsel CA raised its holdings in shares of Amgen by 5.7% in the second quarter. Lederer & Associates Investment Counsel CA now owns 12,988 shares of the medical research company’s stock valued at $2,237,000 after buying an additional 695 shares during the last quarter. Mechanics Bank Trust Department raised its holdings in shares of Amgen by 4.0% in the second quarter. Mechanics Bank Trust Department now owns 3,649 shares of the medical research company’s stock valued at $628,000 after buying an additional 140 shares during the last quarter. Aviance Capital Partners LLC raised its holdings in shares of Amgen by 2.4% in the second quarter. Aviance Capital Partners LLC now owns 39,204 shares of the medical research company’s stock valued at $6,752,000 after buying an additional 919 shares during the last quarter. Finally, Smith Salley & Associates raised its holdings in shares of Amgen by 2.5% in the second quarter. Smith Salley & Associates now owns 19,529 shares of the medical research company’s stock valued at $3,364,000 after buying an additional 472 shares during the last quarter. 78.14% of the stock is owned by institutional investors and hedge funds.
Shares of Amgen Inc. (NASDAQ AMGN) opened at 187.47 on Friday. The firm has a market capitalization of $136.79 billion, a price-to-earnings ratio of 17.08 and a beta of 1.35. The stock has a 50 day moving average of $175.31 and a 200 day moving average of $169.32. Amgen Inc. has a 52-week low of $133.64 and a 52-week high of $191.10.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The company had revenue of $5.81 billion for the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The business’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.84 EPS. On average, analysts predict that Amgen Inc. will post $12.57 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Thursday, August 17th were paid a $1.15 dividend. The ex-dividend date of this dividend was Tuesday, August 15th. This represents a $4.60 annualized dividend and a dividend yield of 2.45%. Amgen’s dividend payout ratio is currently 41.93%.
ILLEGAL ACTIVITY WARNING: “OLD Point Trust & Financial Services N A Trims Stake in Amgen Inc. (AMGN)” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://sportsperspectives.com/2017/09/16/old-point-trust-financial-services-n-a-trims-stake-in-amgen-inc-amgn.html.
AMGN has been the subject of a number of research reports. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $189.00 target price on shares of Amgen in a report on Friday, June 30th. BidaskClub raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a report on Friday, June 23rd. Jefferies Group LLC reaffirmed a “hold” rating and issued a $180.00 target price on shares of Amgen in a report on Monday, May 22nd. Credit Suisse Group set a $177.00 target price on shares of Amgen and gave the company a “hold” rating in a report on Friday, July 14th. Finally, Morgan Stanley upped their target price on shares of Amgen from $183.00 to $184.00 and gave the company an “overweight” rating in a report on Tuesday, June 13th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $186.14.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.